risperidone has been researched along with Aging in 22 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A systematic and comprehensive literature search was performed to determine the extent of weight gain induced by risperidone (RIS) treatment across the age span." | 8.82 | A comparison of risperidone-induced weight gain across the age span. ( Safer, DJ, 2004) |
| "A systematic and comprehensive literature search was performed to determine the extent of weight gain induced by risperidone (RIS) treatment across the age span." | 4.82 | A comparison of risperidone-induced weight gain across the age span. ( Safer, DJ, 2004) |
| "Overall, our data suggest that maternal inflammation may contribute to an increased risk for schizophrenia through mechanisms involving metabolic function and myelin formation and that risperidone in adolescence may prevent or reverse such changes." | 3.81 | Maternal immune activation induces changes in myelin and metabolic proteins, some of which can be prevented with risperidone in adolescence. ( Cagney, G; Cannon, M; Cotter, DR; Dicker, P; English, J; Farrelly, L; Föcking, M; Piontkewitz, Y; Wynne, K, 2015) |
| "Epidermal growth factor (EGF) is one of the ErbB receptor ligands implicated in schizophrenia neuropathology as well as in dopaminergic development." | 3.77 | Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF. ( Aizawa, M; Iwakura, Y; Mizuno, M; Namba, H; Nawa, H; Shcherbakova, K; Sotoyama, H; Wang, R; Zheng, Y, 2011) |
| " The goal of the study was to develop physiologically based pharmacokinetic (PBPK) models for the elderly aged 65+ years." | 1.56 | Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach. ( Hempel, G; Kneller, LA, 2020) |
| " Despite lower dosing in patients >65 versus ≤65 years (median 1." | 1.43 | Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype. ( Haslemo, T; Hoff, M; Molden, E; Waade, RB, 2016) |
| " Future prospective studies are necessary to clarify whether the prescribed dosage should be different in young and older patients." | 1.34 | Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. ( Aichhorn, W; Hinterhuber, H; Kemmler, G; Marksteiner, J; Stuppaeck, C; Walch, T; Zernig, G, 2007) |
| "Risperidone is an atypical antipsychotic drug which has been suggested to be beneficial for the treatment of elderly patients with psychotic symptoms." | 1.31 | The efficacy and safety of risperidone for the treatment of geriatric psychosis. ( Chang, JW; Cheng, CY; Hwang, JP; Tsai, SJ; Yang, CH; Yu, HC, 2001) |
| "Mean risperidone daily dose was 1." | 1.31 | Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects. ( Kastango, KB; Kirshner, MA; Maxwell, RA; Mulsant, BH; Pollock, BG; Rosen, J; Sweet, RA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z | 1 |
| Zong, X | 1 |
| Li, D | 1 |
| He, Y | 1 |
| Tang, J | 1 |
| Hu, M | 1 |
| Chen, X | 1 |
| Kneller, LA | 1 |
| Hempel, G | 1 |
| Qiao, J | 1 |
| Gao, J | 1 |
| Shu, Q | 1 |
| Zhang, Q | 1 |
| Hu, G | 1 |
| Li, M | 1 |
| Farrelly, L | 1 |
| Föcking, M | 1 |
| Piontkewitz, Y | 1 |
| Dicker, P | 1 |
| English, J | 1 |
| Wynne, K | 1 |
| Cannon, M | 1 |
| Cagney, G | 1 |
| Cotter, DR | 1 |
| Molden, E | 1 |
| Waade, RB | 1 |
| Hoff, M | 1 |
| Haslemo, T | 1 |
| Choi, YK | 1 |
| Gardner, MP | 1 |
| Tarazi, FI | 1 |
| Landreville, P | 1 |
| Leblanc, V | 1 |
| Calarge, CA | 1 |
| Miller, del D | 1 |
| Sotoyama, H | 1 |
| Zheng, Y | 1 |
| Iwakura, Y | 1 |
| Mizuno, M | 1 |
| Aizawa, M | 1 |
| Shcherbakova, K | 1 |
| Wang, R | 1 |
| Namba, H | 1 |
| Nawa, H | 1 |
| Sakic, B | 1 |
| Lacosta, S | 1 |
| Denburg, JA | 1 |
| Szechtman, H | 1 |
| Safer, DJ | 1 |
| Zhao, CS | 1 |
| Puurunen, K | 1 |
| Schallert, T | 1 |
| Sivenius, J | 1 |
| Jolkkonen, J | 1 |
| Aichhorn, W | 2 |
| Weiss, U | 1 |
| Marksteiner, J | 2 |
| Kemmler, G | 2 |
| Walch, T | 2 |
| Zernig, G | 2 |
| Stelzig-Schoeler, R | 1 |
| Stuppaeck, C | 2 |
| Geretsegger, C | 1 |
| Haupt, M | 1 |
| Cruz-Jentoft, A | 1 |
| Jeste, D | 1 |
| Leon, Jd | 1 |
| Susce, MT | 1 |
| Pan, RM | 1 |
| Wedlund, PJ | 1 |
| Orrego, ML | 1 |
| Diaz, FJ | 1 |
| Hinterhuber, H | 1 |
| Grant, S | 1 |
| Fitton, A | 1 |
| Sweet, RA | 2 |
| Pollock, BG | 2 |
| Madhusoodanan, S | 1 |
| Suresh, P | 1 |
| Brenner, R | 1 |
| Pillai, R | 1 |
| Zaudig, M | 1 |
| Hwang, JP | 1 |
| Yang, CH | 1 |
| Yu, HC | 1 |
| Chang, JW | 1 |
| Cheng, CY | 1 |
| Tsai, SJ | 1 |
| Maxwell, RA | 1 |
| Mulsant, BH | 1 |
| Rosen, J | 1 |
| Kirshner, MA | 1 |
| Kastango, KB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva[NCT00395499] | 19 participants | Observational | 2001-05-31 | Completed | |||
| Continuation Pharmacotherapy for Agitation of Dementia[NCT00073658] | Phase 2 | 137 participants | Interventional | 2000-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
5 reviews available for risperidone and Aging
| Article | Year |
|---|---|
A comparison of risperidone-induced weight gain across the age span.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Child; Child, Preschool; Humans; Ris | 2004 |
Mortality in elderly dementia patients treated with risperidone.
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Clinical Trials | 2006 |
Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.
Topics: Absorption; Adult; Aged; Aging; Animals; Antipsychotic Agents; Central Nervous System; Cross-Over St | 1994 |
New atypical antipsychotics. Experience and utility in the elderly.
Topics: Aged; Aging; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Imidazoles; Indoles; Olanzapi | 1998 |
A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia.
Topics: Aged; Aging; Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Humans; Risk A | 2000 |
2 trials available for risperidone and Aging
| Article | Year |
|---|---|
A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
Topics: Adult; Aging; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Casse | 2007 |
Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.
Topics: Absorption; Adult; Aged; Aging; Animals; Antipsychotic Agents; Central Nervous System; Cross-Over St | 1994 |
16 other studies available for risperidone and Aging
| Article | Year |
|---|---|
Epigenetic clock analysis of blood samples in drug-naive first-episode schizophrenia patients.
Topics: Aging; DNA Methylation; Epigenesis, Genetic; Humans; Infant; Infant, Newborn; Psychotic Disorders; R | 2023 |
Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antipsychotic | 2020 |
Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon?
Topics: Aging; Animals; Antipsychotic Agents; Avoidance Learning; Conditioning, Psychological; Dopamine Agon | 2014 |
Maternal immune activation induces changes in myelin and metabolic proteins, some of which can be prevented with risperidone in adolescence.
Topics: Aging; Animals; Antipsychotic Agents; Disease Models, Animal; Female; Male; Myelin Sheath; Prefronta | 2015 |
Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Alleles; Antipsychotic Agents; Cytoc | 2016 |
Effects of risperidone on glutamate receptor subtypes in developing rat brain.
Topics: Aging; Animals; Antipsychotic Agents; Autoradiography; Brain; Brain Chemistry; Dose-Response Relatio | 2009 |
Older adult's acceptability ratings of treatments for verbal agitation in persons with dementia.
Topics: Aged; Aged, 80 and over; Aggression; Aging; Behavior Therapy; Dementia; Female; Humans; Male; Neurop | 2010 |
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Topics: Adolescent; Aging; Antipsychotic Agents; Body Mass Index; Child; Child Development Disorders, Pervas | 2011 |
Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF.
Topics: Aging; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Biomarkers; Catalepsy; Dis | 2011 |
Altered neurotransmission in brains of autoimmune mice: pharmacological and neurochemical evidence.
Topics: Aging; Animals; Antibodies, Antinuclear; Autoimmune Diseases; Behavior, Animal; Brain; Brain Chemist | 2002 |
Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury.
Topics: Affect; Aggression; Aging; Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; B | 2005 |
Influence of age and gender on risperidone plasma concentrations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Biotransformation; Chromato | 2005 |
Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents.
Topics: Adolescent; Adult; Aging; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Body Weight; Chil | 2007 |
Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Geriatri | 1999 |
The efficacy and safety of risperidone for the treatment of geriatric psychosis.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chi-Square Dis | 2001 |
Risperidone and 9-hydroxyrisperidone concentrations are not dependent on age or creatinine clearance among elderly subjects.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Creatinine; Female; Humans; Isoxa | 2002 |